17:27 , Sep 14, 2018 |  BC Week In Review  |  Company News

Boehringer to acquire oncolytic virus company ViraTherapeutics

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised an option to acquire oncolytic virus company ViraTherapeutics GmbH (Innsbruck, Austria). Boehringer gained the option under a 2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its...
21:31 , Sep 13, 2018 |  BC Extra  |  Company News

Boehringer adds to immuno-oncology pipeline with ViraTherapeutics acquisition

Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised an option to acquire oncolytic virus company ViraTherapeutics GmbH (Innsbruck, Austria). Boehringer gained the option under a 2016 deal to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its...
00:50 , Feb 25, 2017 |  BioCentury  |  Product Development

mRNA test kitchens

Enough of the early challenges in mRNA have been solved to convince several pharmas and biotechs to enter into partnerships to create products capitalizing on the technology’s advantages over existing modalities. The deals span applications...
07:00 , Sep 28, 2016 |  BC Extra  |  Company News

Boehringer, ViraTherapeutics in oncolytic virus deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with oncolytic virus play ViraTherapeutics GmbH (Innsbruck, Austria) to jointly develop ViraTherapeutics' oncolytic virus therapy platform and its lead candidate, VSV-GP . Boehringer also gained an option to acquire...
07:00 , Jul 14, 2016 |  BC Innovations  |  Strategy

Borderless at Boehringer

With the launch of its new Innovation Unit on July 1, Boehringer Ingelheim GmbH is not only reorganizing its various research teams to streamline R&D, but is ramping up external partnerships to explore new biological...
07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
07:00 , Sep 29, 2014 |  BioCentury  |  Finance

CureVac bet paying off

Although the Hopp family's biotech investments have posted mixed results in recent years, the €80 million marker Hopp put down in 2012 on CureVac GmbH seems to be paying off. The cancer vaccine and infectious...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

CureVac, Boehringer Ingelheim deal

CureVac granted Boehringer exclusive, worldwide rights to develop and commercialize CureVac's CV9202 . The vaccine is in a Phase Ib trial to treat metastatic non-small cell lung cancer (NSCLC). The deal includes a EUR35 million...
02:44 , Sep 19, 2014 |  BC Extra  |  Company News

Boehringer licenses CureVac's CV9202

Boehringer Ingelheim GmbH (Ingelheim, Germany) licensed exclusive, worldwide rights to develop and commercialize CV9202 from CureVac GmbH (Tuebingen, Germany). The candidate is in a Phase Ib trial to treat metastatic non-small cell lung cancer (NSCLC)....